Scabies
Conditions
Brief summary
The ETSKABI study is a prospective, open-label, multicenter, initially single-armed and in case of treatment failure subsequently three-armed randomized clinical trial. Within the initial treatment phase, the to-date clinical efficacy of the standard therapy regimen according to the current German S1-guideline for the diagnosis and treatment of scabies is to be examined. The subsequent second phase focusses on three differently escalated treatment regimens in order to evaluate their potential to cure those patients still suffering from Scabies after standard therapy. In total, 183 patients with Scabies who meet all inclusion criteria and do not meet none of the exclusion criteria are to be enrolled and topically treated with Permethrin 5 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). In case of treatment failure by the end of phase one, adult patients will be randomized to either receive an (i) escalated therapy with Permethrin 5 % cream (repeated topical administration on two consecutive days), (ii) an add-on-combination consisting of escalated therapy with Permethrin 5 % cream and Ivermectin p.o. or (iii) an escalated therapy with Permethrin 10 % cream (up to two administrations, i.e. repeated one-time on day 14 in case of persisting Scabies). The primary objective of the ETSKABI study is the clinical efficacy of the standard therapy by the end of phase one (standard therapy according to the S1-guideline). Beside this, clinical efficacy by the end of phase two (escalation phase) will be evaluated as well as adverse events in order to investigate over-all clinical safety.
Interventions
DRUGInfectoScab 5 % Creme
InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
DRUGPermethrin 10 % Creme
Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
Sponsors
Winicker Norimed GmbH
Infectopharm Arzneimittel GmbH
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed acute scabies disease: detection of mites and/or mite nymphs and/or mite larvae at scabies-typical predilection sites, detected by reflected light microscopy (dermatoscopy) or light microscopy of skin samples. * Age between 6 and 85 years * Written informed consent of the study participant (if of age) or of all guardians (in the case of study participants who are minors \< 12 years of age) or of all guardians and the study participant (in the case of study participants who are minors ≥ 12 years of age).
Exclusion criteria
* Previous treatment with antiscabiosa in the last 14 days. * Known intolerance to permethrin, other pyrethroids, chrysanthemum, ivermectin or any of the other ingredients of the study medication. * Scabies crustosa * Impetiginisation/eczematisation requiring in-patient treatment * Body weight \> 120 kg * Pregnancy, lactation * Immunodeficiency (of any kind, including extensive local therapy (\>20% body surface area) with corticosteroids \>2 weeks in the last 4 weeks or ≥ 10 mg prednisolone equivalent \>7 days in the last 4 weeks- even without signs of scabies crustosa) * Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study (including risk factors for severe COVID-19 disease in the case of SARS-CoV-2 infection). * Planned systemic use of corticosteroids * Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants * Known or clinically suspected blood-brain barrier disruption (e.g. ABCB-1 (=MDR-1) mutation), and history of neurotoxic effects from ivermectin or other substrates/inhibitors of para-glycoprotein (P-gp) * Apparent unreliability or unwillingness to cooperate. * Inability to understand and comply with study instructions * Known alcohol, medication or drug dependence * Court/agency-ordered institutionalisation * Dependence on sponsor or investigator * Previous participation in a clinical trial within the last 30 days or in the same clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy (Yes/No) | day 0 - day 28 | Efficacy (Yes/No) after completed standard therapy treatment cycle (InfectoScab 5 % Creme, up to two administrations, if necessary), i.e. treatment success on day 14 (one administration) or on day 28 (one readministration due to persisting Scabies on day 14). Treatment success is defined as: * absence of new scabietic skin lesions, AND * all remaining scabietic lesions are in healing, AND * exclusion of mite infestation in all non-healed efflorescences by reflected light microscopy (dermatoscope), possibly confirmed by microscopic examination of a skin sample, AND * exclusion of the usage of other anti-scabietic drugs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy (therapy success) for VE5, VE101/2 (separately and cumulatively) and VEK as well as for the corresponding follow-up visits FUE5/E10/EK, separately as well as cumulatively according to visit type (regular visit, FU visit) | day 28 - day 70 | — |
| Cumulative efficacy (treatment success) of permethrin-only treatment (i.e. without combined escalation permethrin + ivermectin) by visit type (regular visit, FU visit) | day 28 - day 56 | — |
| Frequency of required repeated standard therapy as well as escalated therapy. | day 0 - day 70 | — |
| Itch (numerical rating scale (NRS) of 0-10) and change in itch vs baseline (scale differences) for all visits, for standard therapy and escalated therapy, and for escalated therapy additionally the change in itch vs start of escalated therapy. | day 0 - day 70 | — |
| Number and type of body regions affected (wrists/hands, arm pouches, armpits, genital region, groin, knee, feet/ankles/lower legs, head, torso, other) for all visits. | day 0 - day 70 | — |
| Efficacy (treatment success) for VS1 and VS2, as well as for the corresponding follow-up visits FUS1 and FUS2 (separately and cumulatively). | day 14 - day 70 | — |
| Proportion of patients with use of antiscabiosa not conforming to study procedures for all visits, for standard therapy and escalated therapy | day 0 - day 70 | — |
| Proportion of patients with new scabies efflorescences for all treatment cycles and control visits | day 0 - day 70 | — |
| Patients with additionally confirmed therapy failure (in %) | day 0 - day 70 | Proportion of patients with new scabies efflorescences at the end of standard therapy or escalated therapy OR with mite detection by microscopic examination of a skin sample at the aforementioned time points OR use of other antiscabiosa not conforming to the study procedure during the respective therapy cycle. |
| Patients with reinfestation (in %): Proportion of patients with microscopically confirmed new efflorescences at the end of standard therapy or escalated therapy (respective FU-visit) who were assessed as cured at the immediately preceding control visit. | day 0 - day 70 | — |
| Adverse events, serious adverse events, unexpected drug reactions, serious unexpected drug reactions (total frequency, type, severity, causality, with frequencies, with separate presentation of local reactions). | day 0 - day 70 | — |
| Proportion of patients (in %) with evidence of mites (incl. nymphs and larvae, reflecting light microscopy (dermatoscope) or light microscopy of skin samples) for all visits, for standard therapy and escalated therapy | day 0 - day 70 | — |
Countries
Germany
Contacts
Primary ContactAndreas Linke, Dr.
Outcome results
None listed